Leading investments into growth-stage technology and healthcare companies, William Staveacre brings operating and board experience to capital allocation decisions. He evaluates revenue model durability, unit economics, and founder-market fit to prioritize deals that can scale to exit via trade sale or IPO. Active in LP fundraising and syndicate formation, he contributes to portfolio governance and go-to-market execution. Prior roles encompass operating management and investment leadership, providing cross-functional insight into product, sales and financial operations.
Leading investments into growth-stage technology and healthcare companies, William Staveacre brings operating and board experience to capital allocation decisions. He evaluates revenue model durability, unit economics, and founder-market fit to prioritize deals that can scale to exit via trade sale or IPO. Active in LP fundraising and syndicate formation, he contributes to portfolio governance and go-to-market execution. Prior roles encompass operating management and investment leadership, providing cross-functional insight into product, sales and financial operations.
Focuses on growth-stage technology and healthcare companies, prioritizing repeatable revenue models, strong unit economics and clear founder-market fit. Allocates capital with a staged, milestone-driven approach that balances runway extension and go-to-market scaling, targeting exits via trade sale or IPO over a 3–7 year horizon. Employs active board engagement and operating partnership to de-risk commercial execution, leaning toward B2B SaaS, digital health and platform-enabled services. Investment decisions emphasize differentiated product defensibility, measurable growth efficiency and founder alignment; downside risk is managed through conviction-weighted positions and syndicate co-investment.
Focuses on growth-stage technology and healthcare companies, prioritizing repeatable revenue models, strong unit economics and clear founder-market fit. Allocates capital with a staged, milestone-driven approach that balances runway extension and go-to-market scaling, targeting exits via trade sale or IPO over a 3–7 year horizon. Employs active board engagement and operating partnership to de-risk commercial execution, leaning toward B2B SaaS, digital health and platform-enabled services. Investment decisions emphasize differentiated product defensibility, measurable growth efficiency and founder alignment; downside risk is managed through conviction-weighted positions and syndicate co-investment.
| Trades 7059 | Longs Won 2334/7059 33% | Profit Factor 1.82 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $105,688.79 |
| Average Win $43,684.38 | Best Trade (Sep 30) $4.67M | Sharpe Ratio -10.75 |
| Average Loss -$11,875.97 | Worst Trade (Jul 19) -$1.55M | Z-Score -0.84 (59.65%) |
| Commissions $0 | Avg. Trade Length 4m 2w 6d | Expectancy $6,493.27 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 32,258 | 29,032 | 25,806 | 22,581 | 19,355 | 16,129 | 12,903 | 9,677 | 6,452 | 3,226 |